PAD Pipeline 2026: Key Players, MOA, and Clinical Trials

Leading companies like Novo Nordisk, Bayer, and Pluristem are advancing candidates with distinct MOAs. Novo Nordisk's semaglutide targets inflammation, while Bayer's asundexian inhibits Factor XIa. Pluristem's PLX-PAD uses placental cells to promote angiogenesis.

Clinical trials are evaluating both oral and injectable routes of administration, with endpoints focused on walking distance and amputation prevention. Phase III results expected in 2026 could provide first-in-class options for patients with critical limb ischemia. The pipeline also includes drug-coated balloons and gene editing therapies.

The strategic focus on addressing underlying pathophysiology rather than just symptoms marks a paradigm shift. If successful, these therapies could reduce the 30% amputation rate in severe PAD. Market analysts project the PAD treatment market to exceed $5 billion by 2030.

Power Move: The PAD pipeline's shift toward disease-modifying therapies signals a major competitive opportunity. Companies with first-in-class approvals will capture significant market share, while latecomers face an uphill battle. Investors should track Phase III readouts in 2026 as key value inflection points.

This article was edited with AI assistance for readability. Read original here.